Fetuses of mothers with gestational diabetes mellitus are at increased risk to develop perinatal complications mainly due to macrosomia. However, in view of the marked heterogeneity of this disease, it seems difficult to set guidelines for diagnosis and treatment. This complicates the choice of assigning patients either to diet or to insulin therapy. Also of concern is how much benefit could be expected from insulin therapy in preventing fetal complications in these patients. In a systematic review of the literature assessing the efficacy of insulin in preventing macrosomia in fetuses of mothers with gestational diabetes, we found six randomized controlled trials comparing diet alone to diet plus insulin. The studies included a total of 1281 patients (644 in the diet plus insulin group and 637 in the diet group), with marked differences among trials concerning diagnostic criteria, randomization process and treatment goals. Meta-analysis of the data resulted in a risk difference of -0.098 (95%CI: -0.168 to -0.028), and a numbernecessary-to-treat of 11 (95%CI: 6 to 36), which means that it is necessary to treat 11 patients with insulin to prevent one case of macrosomia. This indicates a potential benefit of insulin, but not significantly enough to set treatment guidelines. Because of the heterogeneous evidence available in the literature about this matter, we conclude that larger trials addressing the efficacy of these two therapeutic modalities in preventing macrosomia are warranted. 
Gestational diabetes mellitus (GDM) is defined as carbohydrate intolerance with onset or first recognition during pregnancy showing a marked heterogeneity in terms of the diagnostic and therapeutic approaches. There is a wide variety of diagnostic criteria regarding glucose challenge doses and glycemic thresholds (1) . Moreover, fetuses of women with GDM are at increased risk for perinatal morbidity and mortality, and their relationship with maternal glycemic control is more likely to be a continuum rather than a dichotomous parameter measurable in a satisfactory way by setting a threshold. There also seems to be great difficulty in establishing therapeutic guidelines for such a heterogeneous disease. There is no consensus about the most effective criterion to be used when shifting patients from diet alone to insulin therapy plus diet. The current recommenda-tions of the American Diabetes Association for GDM treatment (2) state that insulin treatment should be initiated if diet therapy fails to maintain plasma glucose values equal to or lower than 5.8, 8.6 and 7.2 mmol/l under fasting conditions and 1 and 2 h after meals, respectively. However, these values are based on observational and retrospective studies correlating glycemic levels and birth weight, without assessing the impact of therapeutic measures in a randomized and controlled fashion. Even oral hypoglycemic agents may have effects similar to those of insulin in the treatment of GDM (3). Moreover, the relationship between insulin treatment alone and the incidence of perinatal complications is unclear.
We performed a systematic review of randomized controlled trials (RCTs) to assess the influence of the treatment of GDM with diet plus insulin in comparison with diet alone on the occurrence of fetal macrosomia. We also assessed secondary outcomes such as birth weight (as a numerical parameter), hypoglycemia, hypocalcemia, hyperbilirubinemia, respiratory distress and congenital malformations. We surveyed the Cochrane Controlled Trials Register, Medline, and Lilacs, as well as reference lists of trials for RCTs published in English, Spanish or Portuguese using the term "diabetes, gestational" combined with the strategy provided in the Cochrane Reviewers' Handbook (4), from 1972 to December 2001. The trials retrieved were selected by reading their abstracts or the entire trial when necessary. This review used RCTs that compared diet alone with diet plus insulin in pregnant women with GDM, regardless of randomization method or diagnostic criterion. Our primary goal was to determine the incidence of fetal macrosomia.
Of the 476 trials using this search strategy, only six (5-10) were RCTs which compared diet alone to diet plus insulin in the treatment of GDM and contained information about macrosomia (Table 1) . We excluded RCTs performing the same interventions but with no information about the desired outcomes, RCTs performing other interventions and studies that were not RCTs.
The total number of patients reviewed was 1281. For macrosomia, risk difference, Petto odds ratio, odds ratio and relative risk analyses favored treatment. Risk difference was -0.098 (95%CI: -0.168 to -0.028) and number-necessary-to-treat was 11 (95%CI: 6 to 36; Table 2 ). Other fetal complications of GDM such as hypoglycemia, hypocalcemia, hyperbilirubinemia and congenital malformations showed no statistically significant differences between the two groups.
The results obtained in this review of the literature show the potential benefit of insulin plus diet for the treatment of GDM in decreasing the incidence of macrosomia compared to diet alone. Nevertheless, methodological problems such as small samples and inadequately described randomization should be solved in larger trials with more adequate randomization and blinding. The external validity of the trials was also impaired by discrepancies involving diagnostic criteria, initial characteristics of patients and definition of the outcomes reviewed. The heterogeneity of these trials impaired the statistical quality of the conclusions of this review.
We conclude that although this review indicates a trend in favor of insulin treatment, this trend is not strong enough to Table 2 . Meta-analysis of effects of insulin treatment on the incidence of macrosomia in the included randomized controlled trials. modify current clinical practice. It was not possible to set guidelines for the treatment of GDM, not only because of the heterogeneity of the trials reviewed, but also because of the heterogeneity in the definition of GDM itself. Moreover, the tendency to treat each case individually is inherent to the treatment of diabetes, further preventing a standardized approach. New RCTs with larger samples and following current diagnostic criteria (2) are necessary to answer these questions.
